Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKYLINE gantenerumab prevention study in preclinical/earliest Alzheimer's disease
NL-OMON50277Phase 3Withdrawn
- Sponsor
- Roche
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of gantenerumab in Alzheimer's disease (AD), sponsored by Roche. Primary endpoint: Change from baseline to Year 4 in PACC-5 score. Planned start Jun 2022; status: withdrawn.
02
Drugs
gantenerumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON50277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50277.